XML 29 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Dispositions | 12 Months Ended
--- | ---
Dec. 31, 2018
Dispositions [Abstract] |
Dispositions | 7. Dispositions On November 4, 2015, XOMA and Ology Bioservices, Inc. (“Ology Bioservices”) entered into an asset purchase agreement under which Ology Bioservices agreed to acquire XOMA’s biodefense business and related assets (including certain contracts with the U.S. government), and to assume certain liabilities of XOMA. As part of the transaction, the parties entered into an intellectual property license agreement (the “Ology Bioservices License Agreement”), under which XOMA agreed to license to Ology Bioservices certain intellectual property rights related to the purchased assets. Under the Ology Bioservices License Agreement, the Company was eligible to receive contingent consideration up to a maximum of $4.5 million in cash and 23,008 shares of common stock of Ology Bioservices, based upon Ology Bioservices achieving certain specified future operational objectives. In addition, the Company is eligible to receive 15% royalties on net sales of any future Ology Bioservices products covered by or involving the related patents or know-how. In February 2017, the Company executed an Amendment and Restatement to both the asset purchase agreement and Ology Bioservices License Agreement primarily to (i) remove the obligation to issue 23,008 shares of Ology Bioservices under the asset purchase agreement, and (ii) revise the payment schedule related to the timing of the $4.5 million cash payments due to the Company under the Ology Bioservices License Agreement. Of the $4.5 million, $3.0 million was contingent upon Ology Bioservices achieving certain specified future operating objectives. In the first quarter of 2017, the Company became entitled to receive $1.6 million under the agreement that was received in quarterly payments through September 2018. In the third quarter of 2017, Ology Bioservices achieved the specified operating objectives and the Company earned the $3.0 million milestone fee that was received in monthly payments through July 2018. Based on the payment terms pursuant to the amended Ology Bioservices License Agreement, the Company is entitled to receive an aggregate of $4.6 million. The Company received $2.4 million during the year ended December 31, 2018, and $2.2 million during the year ended December 31, 2017, which was recognized as other income, net in the consolidated statements of operations and comprehensive (loss) income. No further payments remain under the agreement, but the Company is still eligible to receive royalties in the future.

X
- Definition Dispositions. + References No definition available. + Details
Name: | xoma_DispositionsAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Dispositions disclosure. + References No definition available. + Details
Name: | xoma_DispositionsDisclosureTextBlock
Namespace Prefix: | xoma_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration